{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:36:37Z","timestamp":1790562997657,"version":"4.1.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"\n Importance<\/jats:title>\n Comprehensive clinical data stratified by microsatellite instability (MSI) status in gastroesophageal adenocarcinoma (GEA) are limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize treatment pathways and clinical outcomes following immune checkpoint inhibitor (ICI) therapy in patients with deficient mismatch repair (dMMR) or MSI-high (MSI-H) GEA.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study was conducted from June 2020 to August 2025 at a single tertiary cancer center in Texas. Of 3316 patients diagnosed with GEA, 1638 who underwent MSI testing were included.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n ICI-based therapy with nivolumab plus ipilimumab or with pembrolizumab.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Incidence of dMMR, overall survival, best objective response, clinical or pathological complete response (cCR\/pCR), and clinicopathological factors associated with ICI response.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among the 1638 patients included, the mean (SD) age was 62.5 (12.8) years, and 1204 (73.5%) were male. There were 83 individuals (5.1%) with dMMR tumors. The 3-year overall survival rate for patients with dMMR was 84.7% with and 68.5% without curative-intent surgery vs 72.3% with and 32.3% without curative-intent surgery for patients with proficient mismatch repair. Among the 83 patients with dMMR, 34 had metastatic and 49 had locoregional disease; 30 and 25 patients in each group received ICI-based therapy, respectively, with 16 of 26 evaluable patients (61.5%) achieving best objective response and 12 of 23 (52.2%) achieving pCR\/cCR, respectively (both considered ICI responsive). Among the 25 locoregional cases treated with ICI, 10 proceeded to surgery, with all achieving residual tumor (R0) resection and 3 (30%) demonstrating pCR. Of the remaining patients, 9 achieved cCR and were transitioned to active surveillance. For patients who achieved cCR or pCR, response was reached after 2 to 4 cycles of nivolumab plus ipilimumab or 6 to 12 cycles of pembrolizumab, and none experienced recurrence or death (median [IQR] follow-up after achieving cCR or pCR, 26.0 [16.3-40.0] months). Individuals who were ICI responsive and nonresponsive did not significantly differ in human epidermal growth factor receptor 2 (ERBB2; formerly HER2 or HER2\/neu) status, combined positive score, or claudin-18, isoform 2 (CLDN18.2), expression, whereas Lynch syndrome was more common in responders.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this single-center cohort of dMMR GEA, ICI-based therapy demonstrated high response rates in both metastatic and locoregional settings. The durable responses in locoregional disease suggest the potential to consider nonoperative management in selected individuals. Further research is needed to improve prediction of ICI response and refine treatment strategies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamasurg.2026.0861","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:30:20Z","timestamp":1776267020000},"page":"600","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy Response in Microsatellite Instability\u2013High Gastroesophageal Adenocarcinoma"],"prefix":"10.1001","volume":"161","author":[{"given":"Jun","family":"Okui","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura R.","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather G.","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny J.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariela A.","family":"Blum-Murphy","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer A.","family":"Ajani","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne L.","family":"Hofstetter","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Rice","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Swisher","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Badgwell","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhiko","family":"Ikoma","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"soi260015r1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"soi260015r2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"soi260015r3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.5230\/jgc.2025.25.e33","article-title":"Investigating the synergistic effects of pembrolizumab and chemotherapy in gastric and gastroesophageal junction cancer.","volume":"25","author":"Okui","year":"2025","journal-title":"J Gastric Cancer"},{"key":"soi260015r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102890","article-title":"How do I treat dMMR\/MSI gastro-oesophageal adenocarcinoma in 2025? a position paper from the EORTC-GITCG gastro-esophageal task force.","volume":"134","author":"de la Fouchardi\u00e8re","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"7517","key":"soi260015r5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma.","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"8","key":"soi260015r6","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00332","article-title":"Microsatellite instability is insufficiently used as a biomarker for Lynch syndrome testing in clinical practice.","volume":"8","author":"Papadopoulou","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"soi260015r7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.712760","article-title":"The impact of mismatch repair status on prognosis of patients with gastric cancer: a multicenter analysis.","volume":"11","author":"Guan","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"soi260015r8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bjs.10663","article-title":"Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer.","volume":"105","author":"Polom","year":"2018","journal-title":"Br J Surg"},{"issue":"35","key":"soi260015r9","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"issue":"13","key":"soi260015r10","doi-asserted-by":"publisher","first-page":"8494","DOI":"10.1245\/s10434-024-16340-3","article-title":"Is surgery still the only known cure for gastric cancer?","volume":"31","author":"Badgwell","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"soi260015r11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study.","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"soi260015r12","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2023.41.16_suppl.2591","article-title":"Immunotherapy for localized dMMR\/MSI tumors: first interim analysis of the IMHOTEP trial.","volume":"41","author":"De La Fouchardiere","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"soi260015r13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"soi260015r14","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00492","article-title":"Immune checkpoint inhibitors for mismatch repair-deficient gastroesophageal adenocarcinoma: outcomes and feasibility of nonoperative management at Mayo Clinic.","volume":"9","author":"Sahwan","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"soi260015r15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"issue":"4","key":"soi260015r16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer.","volume":"37","author":"Latham","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"soi260015r17","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach.","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"soi260015r18","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1200\/JCO.22.02462","article-title":"Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: ASCO endorsement of College of American Pathologists guideline.","volume":"41","author":"Vikas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"soi260015r19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.","volume":"457","author":"R\u00fcschoff","year":"2010","journal-title":"Virchows Arch"},{"issue":"10389","key":"soi260015r20","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"soi260015r21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","article-title":"Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.","volume":"20","author":"Kawazoe","year":"2017","journal-title":"Gastric Cancer"},{"issue":"2","key":"soi260015r23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.21037\/acs.2017.03.14","article-title":"8th edition AJCC\/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice.","volume":"6","author":"Rice","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"issue":"6","key":"soi260015r24","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf131","article-title":"Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials.","volume":"112","author":"Okui","year":"2025","journal-title":"Br J Surg"},{"issue":"10294","key":"soi260015r25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"soi260015r27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN Clinical Practice Guidelines in Oncology.","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"soi260015r28","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1007\/s00464-025-11980-2","article-title":"Pragmatic approach to implementation of universal MSI testing for new cases of colorectal cancer.","volume":"39","author":"Poylin","year":"2025","journal-title":"Surg Endosc"},{"key":"soi260015r29","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types.","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"soi260015r30","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/bjs.6172","article-title":"Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer.","volume":"95","author":"Barrow","year":"2008","journal-title":"Br J Surg"},{"issue":"32","key":"soi260015r31","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO-25-00447","article-title":"Neoadjuvant CTLA-4\/PD-(L)1 blockade versus surgery +\/- chemotherapy in deficient mismatch repair\/microsatellite instability-high resectable gastroesophageal adenocarcinoma: individual patient data pooled analysis.","volume":"43","author":"Raimondi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"soi260015r32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007104","article-title":"Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade.","volume":"11","author":"Randon","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"8","key":"soi260015r33","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1158\/0008-5472.CAN-09-3290","article-title":"Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers.","volume":"70","author":"Nagasaka","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"soi260015r34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy.","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"soi260015r22","first-page":"203","volume-title":"AJCC Cancer Staging Manual","author":"Washington","year":"2017","edition":"8th ed"},{"key":"soi260015r26","unstructured":"National Comprehensive Cancer Network Guidelines. Gastric cancer, version 3. Published August 22, 2025. Accessed November 14, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2847686\/jamasurgery_okui_2026_oi_260015_1780929720.17891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:00:47Z","timestamp":1781103647000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2847686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2026.0861","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}